Pyrimethamine Inhibits Human Ovarian Cancer by Triggering Lethal Mitophagy via Activating the p38/JNK/ERK Pathway
Oncology Research · 2025
DOI: 10.32604/or.2025.063724 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Lingjuan Linghu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Wo…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Pyrimethamine, Mitophagy, MAP Kinase Signaling System. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, S…
- Department of Human Anatomy, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Zitieren
APA
Linghu, L., Zhou, H., Zheng, G., & Yi, T. (2025). Pyrimethamine Inhibits Human Ovarian Cancer by Triggering Lethal Mitophagy via Activating the p38/JNK/ERK Pathway. Oncology Research. https://doi.org/10.32604/or.2025.063724
Vancouver
Linghu L, Zhou H, Zheng G, Yi T. Pyrimethamine Inhibits Human Ovarian Cancer by Triggering Lethal Mitophagy via Activating the p38/JNK/ERK Pathway. Oncology Research. 2025. doi:10.32604/or.2025.063724
BibTeX
@article{Linghu2025,
author = {Linghu, Lingjuan and Zhou, Hongying and Zheng, Gang and Yi, Tao},
title = {Pyrimethamine Inhibits Human Ovarian Cancer by Triggering Lethal Mitophagy via Activating the p38/JNK/ERK Pathway},
journal = {Oncology Research},
year = {2025},
doi = {10.32604/or.2025.063724}
}
EUVIMED